ABBV stock forecast: what analysts expect
Wall Street analysts covering AbbVie Inc. currently rate the stock a Buy on average, with a mean 12-month price target of $276.59 — +4.1% versus the last price of $265.79. Targets reflect analyst opinion, not a guarantee.
ABBV historical returns
Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in ABBV.
ABBV annual returns by year
Congress trading in ABBV
35 members of Congress have disclosed trading ABBV — 30 purchases and 24 sales worth an estimated $776,502. Most recent disclosure: May 5, 2026.
See who in Congress traded ABBV →Insider activity in ABBV
ABBV's own executives and directors have made 0 open-market purchases ($0) and 1 sale ($8.2M) in the last 90 days, per SEC Form 4 filings. Most recent: Aug 14, 2026.
| Aug 14, 2026 | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | Sell | $8.2M |
About AbbVie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
ABBV Key Statistics
ABBV in plain English
- P/E ratio (74.7) — how many dollars you pay for each $1 of ABBV's yearly profit. That's high, so the market expects strong growth (and you're paying up for it).
- Profit margin (9.80%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend yield (2.62%) — the cash payout you'd earn per year as a % of the share price, on top of any price gains.
ABBV stock: frequently asked questions
What is AbbVie Inc.'s stock price today?
AbbVie Inc. (ABBV) last traded at $265.79 on the NYSE. Over the past 52 weeks the stock has traded between $190.75 and $267.47.
Is ABBV stock a buy or a sell?
Wall Street analysts' consensus rating on ABBV is "Buy", with an average 12-month price target of $276.59 — about +4.1% versus the current price of $265.79. Analyst targets are opinions, not guarantees; always do your own research.
How much would $1,000 invested in ABBV 10 years ago be worth today?
A $1,000 investment in AbbVie Inc. made 10 years ago would be worth about $6,251 today (dividends reinvested) — a total return of 525%, or 20.1% per year.
Does ABBV pay a dividend?
Yes. AbbVie Inc. currently pays a dividend yielding about 2.62% per year at today's share price.
What is ABBV's P/E ratio?
ABBV trades at a trailing price-to-earnings ratio of 74.7, and 16.3 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.
Do members of Congress trade ABBV stock?
Yes — 35 members of Congress have disclosed trades in ABBV under the STOCK Act, totaling 30 purchases and 24 sales worth an estimated $776,502.
What is AbbVie Inc.'s ticker symbol?
AbbVie Inc. trades under the ticker symbol ABBV on the NYSE.
Compare ABBV with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.